Nscale filed for a New York listing on 18 September against contracted deals of $103.4bn and quarterly revenue just over $100m. Four days earlier Open Cosmos raised €300m from a European syndicate with no American name on it. Underneath both, the ten largest life-sciences raises took 75.2% of British sector capital in the first half of 2026.
Britain can now fund profitable satellite makers at home, but not yet the cash-burning infrastructure bets choosing New York instead.
Nscale lodged its Form S-1 on 18 September, asking American public markets to price $103.4 billion of contracted deals against revenue of just over $100 million a quarter.
Nscale filed a Form S-1 with US regulators on 18 September, seeking a New York Stock Exchange listing at a $14.6bn valuation.
Its contracted order book runs to $103.4bn, but quarterly revenue is only just over $100m, the gap investors will have to price.
Open Cosmos announced a €300 million round on 14 September drawn from a European syndicate with British state money inside it, and named no American investor anywhere in the release.
Open Cosmos, a British satellite company, raised €300m on 14 September from eight institutions including the UK's National Security Strategic Investment Fund.
No American investor joined the round, an unusual choice that points to keeping a dual-use space company clear of US export controls.
Matt Clifford stepped down as chair of the Advanced Research and Invention Agency on 7 September, five days after announcing a move to Anthropic and on the day a Commons committee published its concern.
Matt Clifford resigned as chair of the Advanced Research and Invention Agency on 7 September. He quit five days after announcing a move to Anthropic as managing director for international affairs.
Dame Chi Onwurah's select committee had flagged the conflict. Clifford stepped down rather than contest it.
James Wise undertook in November 2025 that conflicts with his Balderton Capital role would be published on the department's website; a check of the public record on 21 September found no such publication.
James Wise, chair of the Sovereign AI Unit, promised on 21 November 2025 to publish any conflicts with his Balderton Capital role well in advance. Checked on 21 September, no such page exists.
Wise is not a senior civil servant and does not sit on a departmental board. No rule required the publication, so this remains an outstanding undertaking rather than a breach.
The BioIndustry Association found that ten companies absorbed 75.2% of the £2.83 billion deployed into UK life sciences in the first half of 2026, leaving a median round of £600,000.
The BioIndustry Association and Frazier & Deeter reported on 10 September that ten deals took 75.2% of UK life sciences funding in H1 2026. The total raised was £2.83bn.
The typical company raised just £0.6m. A handful of large deals swallowed most of the money, leaving little spread evenly.
The Competition and Markets Authority published "Public procurement in the national interest" on 8 September, questioning whether a system built to count small suppliers does anything for the firms that grow.
The Competition and Markets Authority published a report on 8 September questioning whether Britain's roughly £400bn public procurement system favours high-growth firms.
Chair Doug Gurr and chief executive Sarah Cardell fronted the findings, which point to bidding rules that structurally favour established suppliers.
The British Business Bank said on 7 September it will put up to £150 million into a proposed northern scale-up fund writing tickets of £5 million to £15 million, and named no manager, no close date and no investment criteria.
The British Business Bank said on 7 September it will commit up to £150m to a proposed equity fund. It would back scale-ups across the North of England, with £5m to £15m tickets.
Chancellor John Healey announced the allocation the same day. No manager, close date or criteria have been named yet.
Cambium Networks filed a notice of intention to appoint administrators on 10 September according to the trade outlet ISPreview, while Companies House still showed the company as Active on 21 September.
Cambium Networks filed a notice of intention to appoint administrators on 10 September, trade outlet ISPreview reported. Its Ashburton, Devon site is owned by a Nasdaq-delisted US parent.
Companies House still showed The Firm as Active on 21 September, with no administration filed; the claim rests on one source.
C4X Discovery earned a $13 million milestone payment on 4 September when AstraZeneca moved the licensed compound AZD4916 into its first trial in people.
C4X Discovery earned a $13m milestone payment on 4 September when AstraZeneca moved its licensed compound AZD4916 into a Phase 1 trial.
The licence could be worth up to $400m plus royalties, but most of that value depends on AZD4916 clearing further clinical hurdles.
Imperial spinout Certain Energy raised £10 million on 26 August and Leeds spinout MicroLub raised £7 million on 17 September, both funded without an American lead.
Two university spinouts closed British-backed rounds this month: Certain Energy took £10m with British Business Bank money, and Leeds spinout MicroLub raised £7m with Northern Gritstone backing.
Both show dedicated domestic funds now doing the work once left to overseas investors.
Apollo Therapeutics finished dosing a 144-person trial on 25 August and reports immune responses against all three rhinovirus species from a single shot.
Apollo Therapeutics completed dosing on 25 August in a 144-person Phase 1 trial of a pan-rhinovirus vaccine, with no serious adverse events.
The immune response looked promising across all three targeted virus types, but Phase 1 tests safety, not whether the vaccine actually works.
Expanse, formed by University of Edinburgh students less than a year ago, raised $5.3 million on 16 September for software that sizes a machine-learning job before it runs.
Expanse, founded less than a year ago by University of Edinburgh students, raised a $5.3m seed round on 16 September. Crane Venture Partners led the deal.
Its software predicts the compute an AI training job will need before it runs, targeting the wasted spend from guessing wrong.
Ryft closed a Series B of £20 million led by Gresham House Ventures on 17 September, with Companies House filings corroborating the round's timing but not its size.
Ryft, a Manchester payments company, says it closed a £20m Series B on 17 September led by Gresham House Ventures.
Companies House filings confirm the round's timing but not its £20m size, which rests on the company's own announcement rather than a filed record.
Claret Capital Partners closed a €575 million growth debt fund on 7 September, a 94% step-up on the €297 million it raised for the predecessor fund in 2022.
Claret Capital Partners closed a €575m venture debt fund on 7 September, a 94% step-up on its €297m predecessor fund from 2022.
Unlike equity, venture debt lets growth companies borrow against future revenue without giving up further ownership of the business.
UK Research and Innovation allocated £162 million on 14 September, £95 million to the Henry Royce Institute and £67.7 million to the Rosalind Franklin Institute.
UK Research and Innovation (UKRI) allocated £162m to two national research institutes on 14 September. The Henry Royce Institute took £95m and the Rosalind Franklin Institute took £67.7m.
Both institutes provide shared equipment individual universities and companies could not afford to build on their own.
Project Ventures reached first close on a £5 million Imperial-linked fund on 21 September, with more than 80% of its limited partners drawn from Imperial College London alumni.
Project Ventures hit a £5m first close on 21 September for a new fund built on Imperial College London alumni money.
More than 80% of its limited partners studied at Imperial, a funding model built on graduates backing their own university's founders.
